activity may be limited. Unwanted effects, reflecting its central and autonomic nervous system activity, include insomnia, nervousness, dry mouth, constipation, and excessive sweating. These would not induce toxicity and it seems in our case that mazindol's anorexic activity caused the intoxication. 
Intravenous methylprednisolone in minimal change nephrotic syndrome
Prendisone by mouth in large doses usually reverses minimal change nephrotic syndrome but there may be severe side effects, particularly in patients with frequent relapses. We therefore tried a new regimen beginning with three consecutive pulses of intravenous methylprednisolone and following these with prednisone by mouth in low doses.
Case reports
Eleven patients aged from 4 to 46 were admitted to the study. All had a nephrotic syndrome defined on the basis of hypoalbuminaemia (<25 g/l) and proteinuria (>40 mg/m2/h). Renal 
Studies and results
The table gives clinical details of the five cases of pituitary adenoma (patients [1] [2] [3] [4] [5] reported during the course of the RCGP study and the one (patient 6) reported during the Oxford/FPA study. Patient 2 was taking an oral contraceptive when the pituitary adenoma was diagnosed and patient 5 was a former user. Patients 1, 3, and 4 had never taken an oral contraceptive. The respective periods of observation in the study for current users, former users, and never-users of oral contraceptives were 67 990, 42 622, and 111 252 woman-years. Patients 1 and 4 had had subfertility problems before recruitment to the study and so were not "at risk" of being recruited as oral contraceptive users. They should therefore be excluded from the comparison with the user group. On the other hand, about a quarter of the whole study control group used no form of contraception at the time of recruitment. Many of these subjects may also have had fertility problems and should be similarly excluded from the respective period of observation. With the small number of cases reported here, however, such detailed analysis would not be informative. Patient 6 was recruited in the Oxford/FPA study in the oral contraceptive group (period of observation 69 468 woman-years) but had stopped taking a contraceptive pill before her pituitary adenoma was diagnosed. The periods of observation in the other two groups in the study, consisting of women who used a diaphragm or an IUD, were 31 735 and 22 799 woman-years respectively.
Comment
While no reasonable assessment of incidence can be made from the few observations reported here, the data suggest that there is no substantial increase in the occurrence of pituitary adenomas associated with oral contraceptives. In neither study is there reason to believe that any diagnosed cases have been missed, and perhaps uncontrolled selective hospital-based studies give an exaggerated impression of the frequency of an association. The clinical details in this report show that the temporal relationship between the diagnosis of pituitary adenoma and oral contraceptive use is comFplex. The findings in the only case-control study reported to date5 are in line with our results in that no association between prior use of oral contraceptives and pituitary tumour was detected. Coulam et a15 suggest that the increasing incidence of pituitary tumours that they noted in women of childbearing age is more likely to be due to recent advances in screening methods and surgical procedures than to the use of oral contraceptives. Our own observations point to a similar conclusion, but studies with more extensive data are desirable. 
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